Deeshant Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 08-12-2024
- Paid Up Capital ₹ 8.70 M
as on 08-12-2024
- Company Age 27 Year, 6 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 6.00 M
as on 08-12-2024
- Revenue -83.78%
(FY 2020)
- Profit 70.90%
(FY 2020)
- Ebitda 82.82%
(FY 2020)
- Net Worth 416.40%
(FY 2020)
- Total Assets -4.71%
(FY 2020)
About Deeshant Pharma
The Corporate was formerly known as Rohan Chemicals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 8.70 M.
The company currently has active open charges totaling ₹6.00 M.
Prabhakar Gawans and Rajlaxmi Gawans serve as directors at the Company.
- CIN/LLPIN
U24100MH1997PTC109380
- Company No.
109380
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jul 1997
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Deeshant Pharma Private Limited offer?
Deeshant Pharma Private Limited offers a wide range of products and services, including Anti Infective API, Miconazole Nitrate API, Cardiovascular Drugs & Medication, Cardiac Drugs, Antianginal Drugs, Isosorbide Mononitrate Tablet, API (Active Pharmaceutical Ingredients), Pharma Ingredients & Raw Materials, Muscle Relaxant, Tolperisone HCL Tablet.
Who are the key members and board of directors at Deeshant Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabhakar Gawans  | Director | 11-Jul-1997 | Current |
| Rajlaxmi Gawans | Director | 11-Jul-1997 | Current |
Financial Performance of Deeshant Pharma.
Deeshant Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 83.78% decrease. The company also saw a substantial improvement in profitability, with a 70.9% increase in profit. The company's net worth Soared by an impressive increase of 416.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Deeshant Pharma?
In 2020, Deeshant Pharma had a promoter holding of 95.98% and a public holding of 4.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Shamrao Vithal Co - Op. Bank Ltd. Creation Date: 24 Jan 2004 | ₹0.10 M | Open |
The Shamrao Vithal Co - Op. Bank Ltd. Creation Date: 26 Nov 2002 | ₹5.90 M | Open |
How Many Employees Work at Deeshant Pharma?
Unlock and access historical data on people associated with Deeshant Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Deeshant Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Deeshant Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
